MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Launched by PERSPECTIVE THERAPEUTICS · Dec 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called \[212Pb\]VMT01, which uses alpha particles to target a specific receptor (MC1R) in melanoma cells. The trial aims to find out how safe and effective this treatment is on its own and in combination with another medication called Nivolumab for adults with advanced melanoma that cannot be surgically removed. If you or a loved one has been diagnosed with Stage III or IV melanoma and have not responded well to previous treatments, this trial might be an option to consider.

To be eligible for the trial, participants need to be at least 18 years old and have measurable melanoma that has not improved with earlier therapies. They should also be able to lie still for imaging scans and have satisfactory organ function. Those who join the trial will receive the new treatment and be monitored closely for any side effects or changes in their condition. It’s important to note that certain health conditions and recent treatments may exclude someone from participating, so discussing eligibility with a healthcare provider is essential.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to understand and willingness to provide informed consent, willingness to comply with all study procedures for the duration of the study
• • Aged ≥ 18 years
• • Diagnosed with unresectable Stage III or Stage IV metastatic melanoma
• • Previously progressed (clinical or radiological progression) on at least one approved first-line therapy for metastatic melanoma
• • Uptake of \[68Ga\]VMT02 or \[203Pb\]VMT01 by PET or SPECT imaging observed in at least one melanoma tumor site using quantitative imaging analysis compared to reference normal tissue
• • Subjects on prior intravenous therapy (e.g., chemotherapy or checkpoint inhibitors), or prior oral therapy (e.g.,proto-oncogene B-RAF or mitogen-activated extracellular signal-regulated kinase inhibitors) who demonstrate MC1R positivity during screening are eligible for enrollment, provided that they undergo a wash-out period of 21 days, or 7 days, respectively, prior to Cycle 1 Day 1 treatment with \[212Pb\]VMT01.
• • Presence of measurable disease by RECIST v1.1 assessed within 30 days prior to the first dose of \[212Pb\]VMT01 on Cycle 1 Day 1
• • Ability to lie flat and still for up to two hours for imaging scans; moderate conscious sedation allowed if indicated
• • For females of reproductive potential: agree to use of highly effective contraception and refrain from donating eggs (ova, oocytes) for the purpose of reproduction starting from screening, during treatment with \[212Pb\]VMT01 and/or nivolumab, and for at least 6 months after the last dose of \[212Pb\]VMT01 and/or nivolumab, whichever is administered last
• • For males of reproductive potential: agree to use of condoms or other methods to ensure effective contraception and refrain from donating sperm starting from screening, during treatment with \[212Pb\]VMT01 and/or nivolumab, and for at least 6 months after the last dose of \[212Pb\]VMT01 and/or nivolumab, whichever is administered last
• • Eastern Cooperative Oncology Group performance score of \< 2 at Screening
• • Life expectancy of at least 3 months after Cycle 1 Day 1
• • Satisfactory organ function determined by laboratory testing
• Exclusion Criteria:
• • Active secondary malignancy
• • Prior systematic treatment with radioactive nuclides. Subjects who had localized treatment with radioactive nuclides or imaging using radioactive imaging agents may be enrolled
• • Pregnancy or breastfeeding a child
• • Any serious/active/uncontrolled infection requiring parenteral antibiotics within 2 weeks before the first administration of \[212Pb\]VMT01
• • Febrile illness within 48 hours of any scheduled investigational product (\[212Pb\]VMT01, \[203Pb\]VMT01, or \[68Ga\]VMT02) administration; subjects should be rescheduled \> 48 hours after resolution of fever
• • Treatment with another investigational drug product (therapeutic IND agents) within the last 45 days before the first dose of \[212Pb\]VMT01 on C1D1.
• • Current abuse of alcohol or illicit drugs
• • Existence of any medical or social issues likely to interfere with study conductor that may cause increased risk to the subject or to others, e.g., lack of ability to follow radiation safety precautions
• Additional exclusion criteria for subjects who will receive combination therapy with nivolumab:
• • Untreated central nervous system (CNS) metastasis or metastasis requiring acute therapy of any modality. Subjects must have been either off corticosteroids, or on a stable or decreasing dose of prednisone (or equivalent) for at least 2 weeks prior to the first dose of \[212Pb\]VMT01
• • Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of \[212Pb\]VMT01
• • Subjects with an active, known, or suspected autoimmune disease
• • Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
• • Acute or chronic hepatitis B (e.g., Hepatitis B surface antigen reactive), hepatitis C (e.g., HCV RNA \[qualitative\] is detected) or known history of Human Immunodeficiency Virus (HIV) with an acquired immunodeficiency syndrome
• • Treatment with complementary medications (e.g., herbal supplements or traditional Chinese medicines)
• • Existence of abnormal laboratory values in hematology, liver, and renal function
• • Treatment with any live/attenuated vaccine within 30 days prior to the first dose of \[212Pb\]VMT01
• • Any treatment-related toxicities from prior systemic immune therapy with the exception of those unlikely to re-occur with standard countermeasures
• • History of allergy or hypersensitivity to nivolumab or its components